Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This I/II trial studies the side effects and best dose of lenalidomide when given together
with nivolumab and to see how well they work in treating patients with non-Hodgkin or Hodgkin
lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as
nivolumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in
chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving nivolumab and lenalidomide may work better in treating patients with
non-Hodgkin or Hodgkin lymphoma.